Log In
BCIQ
Print this Print this
 

CLS-1003

  Manage Alerts
Collapse Summary General Information
Company Clearside Biomedical Inc.
DescriptionTriamcinolone acetonide and an undisclosed anti-VEGF delivered using the company's ocular microinjection platform
Molecular Target Glucocorticoid receptor (GCCR) ; Vascular endothelial growth factor (VEGF)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMacular edema
Indication DetailsTreat macular edema associated with retinal vein occlusion (RVO)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today